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LETTER TO THE EDITOR

COVID-19 in Hemodialysis
Patients

suspected cases. Eﬀectively, prevention of the spread of infection
among HD centres, healthcare personnel, and patients is essential to ensure the safety of all stakeholders as well as continued
delivery of HD to patients.

Sir,

PATIENTS CONSENT:
Not applicable (All data were obtained from electronic and ﬁlebased medical records and the Institutional Review Board waived
oﬀ the need for informed consent).

’

Patients on maintenance hemodialysis (HD) are commonly
aﬀected with multiple comorbidities and are also prone to infections due to uremia-induced suppressed immunity, making them
1,2
more vulnerable to COVID-19. The altered immune state
together with associated comorbidities and impractical social
distancing due to inevitable frequent visits to dialysis unit poses
threat of severe COVID-19. The risk may further increase in HD
patients of low income countries due to lack of facilities and limitation of implementation of epidemiologic measures for infection
control. Studies from various parts of the world have reported
varying prevalence, clinical presentations and case fatalities.
Prevalence ranging 2-28% with regional variations and a higher
mortality rate 14-51% has been observed compared to general
population.3-5 Moreover, the clinical presentation of COVID-19
may range from asymptomatic to non-speciﬁc symptoms that
may be attributed to dialysis, such as shortness of breath or cough
from ﬂuid overload and; hence, poses challenge in prompt diagnosis of disease in this group. There is limited information on symptoms, laboratory and radiologic abnormalities and outcomes of
COVID-19 in patients on HD from Pakistan.
We reviewed clinical presentation and short-term outcomes of
COVID-19 in patients on HD at our centre. Out of 108 patients,
13.9% (n=15) were aﬀected by COVID-19. Mean age was 62.8 ±
8.6 years and 53.3% were females. Most common cause of kidney
failure was diabetic kidney disease (80%; n=12), unknown
etiology (13.3%, n=2), chronic glomerulonephritis (6.7%, n=1).
Among comorbid conditions, hypertension was the most prevalent (100%), followed by diabetes mellitus (86.7%) and ischemic
heart disease (33.3%). One patient had chronic obstructive pulmonary disease (COPD) and another had active malignancy; and was
on chemotherapeutic treatment. Forty percent of the patients
were asymptomatic. Among symptomatic patients, shortness of
breath was commonest (40%; n=6), followed by cough (26.7%;
n=4) and fever (20%; n=3). Half of the patients required hospitalisation; and more than two-thirds of those required invasive or
non-invasive ventilation. The mortality rate observed was 40%.
Compared to survivors, deceased patients were signiﬁcantly
older and had higher inﬂammatory markers including C-reactive
protein, ferritin, procalcitonin, lactate dehydrogenase.
Lymphopenia, a universal ﬁnding in COVID-19, was not observed;
and only 40% patients had radiological ﬁndings consistent with
COVID-19 at the time of presentation.
Given the high mortality rates, patients on maintenance HD are
considered as a high-risk population for poor outcomes. A wide clinical presentation and asymptomatic nature of disease in some
cases emphasise the need for high clinical suspicion as well as
implementation of proactive measures in screening and isolating
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